The therapeutic community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to offer a greater substantial decrease in body weight and benefit metabolic markers, par